# Pfizer (PFE) - Re-evaluation v2.0

**Date:** 2026-02-03
**Status:** HOLD - FAIRLY VALUED

## Summary
| Metric | Original | v2.0 |
|--------|----------|------|
| Fair Value | $32-35 | $27.52 (-20%) |
| MoS | 25-36% | 3-10% |
| WACC | 8% assumed | 8% derived |
| Value Trap | N/A | 2/10 |

## Key Findings
- Big pharma post-COVID transition
- DCF + DDM appropriate methods
- Patent cliff 2026-28 already priced
- Dividend maintained (6.84% yield)

## Earnings (Feb 3, 2026)
- FY2026 guidance: $2.80-3.00 EPS (INLINE)
- Dividend: $0.43/Q MAINTAINED

## Action
HOLD. No ADD at current prices. ADD trigger at $24.
